×
About 612,445 results

WFH Guidelines for the Management of Hemophilia, 3rd edition
https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
Haemophilia

Aug 3rd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 10th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200216/full/

Jun 25th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...

Autoantibodies May Predict Disease Response in Metastasized Melanoma Treated With Checkpoint Inhibitors
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200204/full/

May 30th, 2020 - There is a diverse and broad autoantibody response to tumor and autoimmune disease antigens in melanoma treated with checkpoint inhibitors (CPIs). Results from a recent study presented during the ASCO20 Virtual Scientific Meeting show that some of those autoantibodies correlate to clinical outcomes and immune-related adverse events (irAEs; Abstract 10011).

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 29th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer
https://www.targetedonc.com/view/parp-inhibition-improves-outcomes-in-patients-with-brca-mutated-ovarian-cancer

May 29th, 2020 - David O'Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, and director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200124/full/

May 13th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) inhibitors has shown promise for people with CLL, with the BTK inhibitor ibrutinib now considered a standard of care for patients of any age. However,...

Combination Immunotherapy Could Be a Potential Treatment Option for Rare Gynecologic Cancers, Pending Randomized Trial Validation
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200122/full/

May 13th, 2020 - The novel combination of immune checkpoint inhibitors ipilimumab and nivolumab may offer patients with rare gynecologic neoplasms the opportunity for improved outcomes, according to a new study (Abstract 6091) that will be presented during the ASCO20 Virtual Scientific Program.

Antihypertensive drugs and risk of COVID-19?
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30153-3/fulltext
The Lancet Respiratory Medicine;

Mar 26th, 2020 - Lei Fang and colleagues1 suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the e...

Statins and the COVID-19 main protease: in silico evidence on direct interaction
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212226/
Archives of Medical Science; Reiner Z

Apr 25th, 2020 - No proven drug and no immunisation are yet available for COVID-19 disease. The SARS-CoV-2 main protease (Mpro), a key coronavirus enzyme, which is a potential drug target, has been successfully crystallised. There is evidence suggesting that statins exert anti-viral activity and may block the infectivity of enveloped viruses. The aim of this study was to assess whether statins are potential COV...

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742232/
PLOS Medicine; Ruscitti P

Sep 16th, 2019 - The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor antagonist, could improve both glycaemic and inflammatory parameters in participants with RA and T2D compared wit...

The Hypotensive Role of Acupuncture in Hypertension: Clinical Study and Mechanistic Study
https://www.frontiersin.org/articles/10.3389/fnagi.2020.00138/full

As a component of traditional Chinese medicine (TCM), acupuncture has the potential to lower blood pressure (BP) in patients with hypertension. Emerging evidence indicates that the acupuncture-induced inhibition of high BP occurs through the activation of the pathway in the afferent, central, and efferent pathways. An increasing number of studies have demonstrated that acupuncture not only acti...

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
https://www.nejm.org/doi/full/10.1056/NEJMoa2007621
The New England Journal of Medicine;

Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.

Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1758791
Journal of Biomolecular Structure and Dynamics;

In December 2019, COVID-19 epidemic was described in Wuhan, China, and the infection has spread widely affecting hundreds of thousands. Herein, an effort was made to identify commercially available drugs in order to repurpose them against coronavirus by the means of structure-based virtual screening. In addition, ZINC15 library was used to identify novel leads against main proteases. Human TMPR...

Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations
https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1758790
Journal of Biomolecular Structure and Dynamics;

The new Corona-virus, recently called the severe acute respiratory syndrome Coronavirus (SARS-CoV-2) appears for the first time in China and more precisely in Wuhan (December 2019). This disease can be fatal. Seniors, and people with other medical conditions (diabetes, heart disease…), may be more vulnerable and become seriously ill. This is why research into drugs to treat this infection remai...

Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from ...
https://doi.org/10.1007/s00228-022-03357-4 10.1093/eurheartj/ehn579 10.1371/journal.pone.0024964 10.1093/eurheartj/ehi505 10.1093/europace/eun369 10.1093/europace/euab065 10.1182/bloodadvances.2020001830 10.1016/j.jacc.2020.09.011 10.1016/j.ijcard.2020.06.032 10.1093/eurheartj/ehaa612 10.1161/CIR.0000000000000665 10.1016/0002-9343(94)90131-7 10.1378/chest.10-0134 10.1007/s11739-018-1858-2 10.1056/NEJMoa1009638 10.1093/europace/euz361 10.1007/s00392-017-1102-5 10.1016/S0140-6736(13)62343-0 10.1055/s-0038-1627480
European Journal of Clinical Pharmacology; Zhang Q, Ding Q et. al.

Jul 2nd, 2022 - The aim of this study was to analyze the clinical characteristics of fatal adverse events (AEs) of rivaroxaban combined with aspirin and to underline the importance of the rational use of drugs. The WHO global database of reported potential side effects of medicinal products (VigiBase) was searched for fatal AEs in the combined use of rivaroxaban and aspirin, and the clinical characteristics of...

The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti...
https://doi.org/10.1007/s00262-022-03240-2 10.1016/j.immuni.2016.04.023 10.1038/nrc.2016.36 10.1158/1078-0432.Ccr-13-3271 10.1056/NEJMoa1200690 10.1016/s0140-6736(17)31827-5 10.1073/pnas.1705327114 10.1158/1078-0432.Ccr-18-1449 10.1007/s00262-018-2225-x 10.3389/fimmu.2018.00014 10.4049/jimmunol.178.7.4112 10.1084/jem.186.9.1407 10.1084/jem.20030235 10.1002/eji.200525983 10.1002/cyto.a.20643 10.1016/j.bbrc.2016.08.115 10.1093/jjco/hyaa202 10.1001/jamaoncol.2018.0013 10.1016/s0140-6736(18)31257-1 10.1001/jamaoncol.2020.3370 10.1007/s10120-016-0631-3 10.1016/s1470-2045(20)30169-8 10.1038/nri.2015.3 10.1158/0008-5472.Can-15-1545 10.1038/s41416-020-0813-y 10.1186/s40425-018-0399-6 10.1158/1078-0432.Ccr-13-1877 10.4049/jimmunol.1402711 10.1016/j.cellimm.2018.02.002 10.1158/1078-0432.Ccr-17-2257 10.1016/j.ctrv.2016.11.007 10.1126/science.aaa1348 10.1056/NEJMoa1406498 10.1038/s41467-018-05072-0 10.1158/1078-0432.Ccr-13-0945 10.1002/ijc.26297 10.1158/2326-6066.Cir-14-0239 10.1186/s13059-019-1921-y 10.1038/nm.4051 10.1080/25785826.2019.1698261 10.1158/2326-6066.Cir-15-0210 10.1093/intimm/dxx073 10.1038/s41586-021-03752-4
Cancer Immunology, Immunotherapy : CII; Nose Y, Saito T et. al.

Jul 2nd, 2022 - Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in patients with gastric cancer. We collected peripheral blood samples from gastric cancer patients (n = 29) before...

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskel...
https://doi.org/10.1007/s00520-022-07243-8 10.1056/NEJMoa032312 10.1016/S0140-6736(15)61074-1 10.1007/s10549-010-1132-4 10.1200/JCO.2011.38.0261 10.1016/j.clbc.2017.1003.1002 10.5301/tj.5000376 10.1186/1471-2407-1113-1401 10.1002/art.21364 10.1093/annonc/mdt1513 10.1002/cncr.24419 10.1016/S1470-2045(1008)70182-70187 10.1200/JCO.2007.3810.7573 10.1007/s00520-00017-03613-z 10.1007/s10549-013-2638-3 10.1007/s10549-014-2873-2 10.1007/s10549-015-3378-3 10.1371/journal.pone.0068798 10.2217/pgs-2016-0205 10.1200/JCO.2010.28.5064 10.1371/journal.pone.0247989 10.1152/physiolgenomics.00085.2017 10.1007/s10549-013-2504-3 10.1097/FPC.0000000000000429 10.1002/cncr.25385 10.1634/theoncologist.2015-0349 10.1038/clpt.2011.174 10.1038/ng.3656 10.1111/bcp.13130 10.1016/j.clbc.2017.1010.1009 10.1016/j.breast.2019.1010.1008 10.1007/s10549-10020-05656-10549 10.1093/bioinformatics/btv3402 10.1101/gr.137323.137112 10.1002/humu.23791 10.1186/s13059-13016-10926-z 10.1186/s12014-12018-19215-z 10.1097/LGT.0000000000000498 10.1074/jbc.M107558200 10.1016/j.neuroscience.2009.1010.1007 10.3390/ijms21165709 10.1038/emboj.2009.1321 10.31074/jbc.M36113.486910 10.1371/journal.pone.0213387 10.1002/cpt.590 10.1200/JCO.2021.39.15_suppl.12003 10.1371/journal.pone.0133964 10.3389/fgene.2021.662734 10.1001/jama.2017.7156 10.1200/OP.1220.00113 10.1200/JCO.2017.74.6651 10.1007/s10549-10018-14811-10541 10.1200/JCO.2009.26.3756 10.1093/hmg/dds381 10.1016/j.ajhg.2016.07.017 10.1038/nature24284 10.1371/journal.pcbi.1004219 10.1002/cam1004.1256
Supportive Care in Cancer : Official Journal of the Multi... Hertz DL, Douglas JA et. al.

Jul 2nd, 2022 - Aromatase inhibitors (AIs) are commonly used to treat hormone receptor positive (HR +) breast cancer. AI-induced musculoskeletal syndrome (AIMSS) is a common toxicity that causes AI treatment discontinuation. The objective of this genome-wide association study (GWAS) was to identify genetic variants associated with discontinuation of AI therapy due to AIMSS and attempt to replicate previously r...

What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strate...
https://doi.org/10.1007/s12017-022-08718-x 10.1016/S0140-6736(17)31585-4 10.3233/JPD-181329 10.1093/brain/aws009 10.3233/JPD-140364 10.1016/s0730-725x(98)00155-6 10.1002/mds.23616 10.1016/j.neuroimage.2011.08.077 10.1016/j.expneurol.2012.01.011 10.3233/JPD-171203 10.1212/WNL.0b013e3181d55f38 10.1371/journal.pone.0024817 10.1097/00001756-199406020-00006 10.1002/mds.25380 10.3233/JAD-2010-091525 10.1093/brain/122.8.1437 10.1016/j.clineuro.2020.105878 10.1016/j.neuroimage.2012.12.040 10.1002/mds.26291 10.1126/science.1087753 10.1002/mds.1112 10.1074/jbc.M710012200 10.1089/ars.2013.5593 10.3233/JPD-130230 10.1177/1545968311421614 10.1056/NEJMoa033447 10.1002/mds.23829 10.1177/1545968314542981 10.1186/s12883-015-0331-3 10.1016/B978-012547626-3/50022-3 10.1002/mds.22402 10.3233/JPD-160965 10.1097/01.jnen.0000225906.82428.69 10.1126/science.1709304 10.1586/14737175.2014.877842 10.2174/187152709789824606 10.1152/jn.00760.2007 10.1016/S2215-0366(16)00104-8 10.1097/NPT.0000000000000249 10.1097/00001756-199110000-00012 10.1212/WNL.0b013e31829d873c 10.1212/WNL.0000000000004572 10.1002/mds.23983 10.1016/j.jep.2014.08.031 10.1159/000377676 10.3233/jad-2004-6s610 10.1053/apmr.2000.4439 10.1371/journal.pone.0157602 10.1002/cpt.1548 10.1136/jnnp-2012-303182 10.1371/journal.pone.0214364 10.1002/mds.27131 10.1056/NEJMoa0809335 10.3233/JAD-121990 10.1007/s12035-018-0908-0 10.1212/01.wnl.0000215250.82576.87 10.1212/01.wnl.0000204007.46190.54 10.1523/jneurosci.17-04-01377.1997 10.1016/j.jep.2019.112226 10.1002/mds.25945 10.1016/s1474-4422(11)70073-4 10.1016/S0014-4886(03)00341-8 10.1007/s10072-015-2201-6 10.1002/ana.410440726 10.1093/ijnp/pyaa060 10.1016/s1474-4422(13)70117-0 10.1001/jamaneurol.2017.3517 10.1001/archneur.2008.65.6.nct70003 10.1001/jamaneurol.2013.5528 10.1016/j.freeradbiomed.2009.11.026 10.1159/000116869 10.1002/ana.410440724 10.1212/wnl.56.4.455 10.1186/s12883-019-1252-3 10.1016/s0306-4522(98)00004-9 10.1002/mds.23148 10.1007/s12017-018-8511-0 10.1002/mds.25561 10.1001/archneur.64.7.nct60005 10.1136/bmjopen-2014-005158 10.1007/s00702-019-02082-0 10.1002/mds.26659 10.1016/S1474-4422(19)30285-6 10.1126/science.1710829 10.1056/NEJMoa1809983 10.1186/1471-2318-13-54 10.1016/j.bmc.2014.09.033 10.1002/ana.10609 10.1016/j.parkreldis.2015.05.022 10.1186/s12974-014-0226-z 10.9734/EJMP/2016/26453
Neuromolecular Medicine; Ong WY, Leow DM et. al.

Jul 2nd, 2022 - Research advances have shed new insight into cellular pathways contributing to PD pathogenesis and offer increasingly compelling therapeutic targets. In this review, we made a broad survey of the published literature that report possible disease-modifying effects on PD. While there are many studies that demonstrate benefits for various therapies for PD in animal and human studies, we confined o...

Catalysis-independent ENPP1 protein signaling regulates mammalian bone mass.
https://doi.org/10.1002/jbmr.4640
Journal of Bone and Mineral Research : the Official Journ... Zimmerman K, Li X et. al.

Jul 2nd, 2022 - Bi-allelic ENPP1 deficiency induces vascular/soft tissue calcifications in Generalized Arterial Calcification of Infancy (GACI), and low bone mass with phosphate-wasting rickets in GACI survivors (Autosomal Hypophosphatemic Rickets Type-2). ENPP1 haploinsufficiency induces early-onset osteoporosis and mild phosphate-wasting in adults. Both conditions demonstrate the unusual combination of reduc...